Our rep/cap plasmids provide the appropriate packaging functions for AAV-based gene therapeutics.
Recombinant AAV (rAAV) manufacturing is composed of four main components which include a rep/cap plasmid, a helper plasmid, a transgene plasmid, and a viral packaging cell line. Triple transfection of the three plasmids into HEK293 cells is the most frequently used rAAV production method.
What are the advantages of using standardized plasmids? As James Brown explains, large scale production of these plasmids for gene therapy offer researchers the opportunity to lower costs on their projects while working with shorter timelines.